Covid-19 vaccine COVAXIN update: Phase 2 human trials begin at Nagpur Hospital

By: |
New Delhi | August 11, 2020 3:18 PM

COVAXIN vaccine latest news, Coronavirus vaccine in India: It took 30 days for ‘COVAXIN’ to successfully complete the Phase 1 trial in India. As many as 12 sites have been selected for the human trials of ‘COVAXIN’.

COVAXIN vaccine latest news, COVAXIN trial, COVAXIN vaccine, COVAXIN launch, COVAXIN covid 19 vaccine, COVAXIN launch date, COVAXIN results, Coronavirus vaccine, Coronavirus vaccine updates, Coronavirus vaccine in India, Coronavirus vaccine status, Coronavirus vaccine tracker, Coronavirus vaccine trials COVAXIN Human Trial: A vaccine needs to go through the rigorous three phases of human trials.

Coronavirus COVID19 vaccine update: In a significant progress, Phase 2 clinical human trials of India’s first indigenous experimental coronavirus vaccine candidate ‘COVAXIN’ began on Tuesday in Nagpur. Phase 2 clinical trials are beginning today at Gillurkar Hospital and Research Institute in Nagpur. Hyderabad-based biotech firm Bharat Biotech is developing the COVID19 vaccine candidate in collaboration with the Indian Council of Medical Research (ICMR), and the National Institute of Virology, Pune.

It took 30 days for ‘COVAXIN’ to successfully complete the Phase 1 trial in India. As many as 12 sites have been selected for the human trials of ‘COVAXIN’. The 12 test sites are All India Institutes of Medical Sciences (AIIMS) New Delhi, AIIMS Patna, PGI Rohtak in Haryana, Redkar Hospital in Goa, and Institute of Medical Sciences and SUM Hospital in Bhubaneswar. Apart from these, COVIXIN clinical test sites are located in Andhra Pradesh’s Visakhapatnam, Karnataka’s Belgaum, Maharashtra’s Nagpur, Uttar Pradesh’s Gorakhpur and Kanpur, Tamil Nadu’s Kattankulathur, and Telangana’s Hyderabad.

Earlier, Chairman and MD Bharat Biotech International Krishna Ella said that safety and quality of the COVAXIN would be ‘paramount’. Even though there was tremendous pressure on the company, the firm won’t “kill more people with the wrong vaccine.”

COVAXIN has been categorized as an “inactivated vaccine”. COVAXIN is being developed by using particles of the Coronavirus that have been killed. These particles are unable to infect and replicate. Bharat Biotech revealed that particular doses of these particles would be injected into the human body. These will help build immunity within the human body and create antibodies against the virus.

A vaccine needs to go through the rigorous three phases of human trials. The Central Drugs Standard Control Organisation in India has given its nod for Phase 1 and Phase 2 trials so far.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Positivity rate below 4 per cent for 5 days would mean Delhi has been successful in combating COVID-19: Satyendar Jain
2Important to have large basket of COVID-19 vaccine candidates: DBT Secy
3Delhi govt tells healthcare facilities to submit HCWs data for COVID-19 vaccination